Ratings Carl Zeiss Meditec AG Wiener Boerse

Equities

AFX

DE0005313704

Real-time Estimate Tradegate Other stock markets 01:28:00 20/06/2024 am IST			5-day change	1st Jan Change
65.42 ^EUR	-22.16%		-3.00%	-14.76%

03:36pm	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades
18/06	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The firm trades with high earnings multiples: 27.65 times its 2024 earnings per share.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CARL ZEISS MEDITEC AG	-14.76%	6.38B	-
THERMO FISHER SCIENTIFIC	+7.23%	217B	B
DANAHER CORPORATION	+11.31%	191B	B-
INTUITIVE SURGICAL, INC.	+28.94%	154B	B-
BOSTON SCIENTIFIC CORPORATION	+32.00%	112B	A-
SIEMENS HEALTHINEERS AG	-0.46%	62.84B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.09%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.94%	48.83B	B+
AGILENT TECHNOLOGIES, INC.	-2.97%	39.36B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.23%	35.73B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes